You are here: Industry Insights > Migraine

News List

Biohaven and Pfizer announce results of rimegepant trial for acute treatment of migraine ExpressPharma
February 15, 2022
This is the fourth positive phase-III study of rimegepant for the acute treatment of migraine, and the first to be conducted in the Asia Pacific.
Mindfulness-Based Cognitive Therapy Beneficial in Migraine drugs
January 10, 2022
A migraine-specific adaptation of the Mindfulness-Based Cognitive Therapy (MBCT) program does not improve headache-related impairment...
Vitamin D Supplementation Could Reduce Migraine Headache Attacks drugs
January 10, 2022
Vitamin D supplementation could reduce headache attacks per month and headache days per month among migraine patients, according to a review published in the December issue of The American Journal of Emergency Medicine.
Pfizer and Biohaven close collaboration agreements pharmaceutical-business-review
January 06, 2022
pfizer has completed the collaboration transaction with Biohaven Pharmaceuticals to obtain rights to market the latter’s rimegepant and zavegepant outside of the US.
Hormone exposure in the womb potentially linked to migraine risk in later life FirstWordPharma
December 17, 2021
Hormone levels in the womb before birth have been potentially linked to the risk of developing migraine in adulthood, reveals a new study of genetic and environmental information from the world's largest database of twins.
Patients benefited from telemedicine during COVID-19, says new white paper from Healint prnasia
November 12, 2021
A new white paper from healthcare analytics platform provider Healint shows that most patients with migraine and other comorbidities had positive experiences with telemedicine, especially during the COVID-19 pandemic.
BioDelivery Sciences to Acquire U.S. and Canadian Rights to ELYXYB™ for Migraine Treatment americanpharmaceuticalreview
August 05, 2021
BioDelivery Sciences International Inc., a growing specialty pharmaceutical company dedicated to patients living with serious and complex chronic conditions, announced that it entered into an agreement on August 3, 2021 with Dr. Reddy’s Laboratories ...
Lilly plans head-to-head migraine study comparing Emgality with Nurtec ODT pharmatimes
June 18, 2021
Eli Lilly is planning to conduct a head-to-head study comparing its calcitonin gene-related peptide (CGRP) monoclonal antibody (mAb) Emgality with Biohaven Pharmaceuticals’ Nurtec for the preventative treatment of migraine.
A Real Headache: Racism Plays Role in Migraine Care drugs
June 11, 2021
The color of your skin may very well determine how your headache gets treated, a new study warns.
FDA Approves Biohaven's NURTEC® ODT: First and Only Migraine Medication for both Acute and Preventive Treatment americanpharmaceuticalreview
June 02, 2021
Biohaven Pharmaceutical Holding Company announced that the U.S. FDA has approved NURTEC® ODT (rimegepant 75 mg) for the preventive treatment of migraine.

Previous page 1 2 3 4 5 6 7 8 9 Next page